PMN310 has been granted Fast Track Designation by the U.S. FDA for the treatment of Alzheimer’s disease.
ProMIS Neurosciences, Inc. Sitemap
Browse the links below for pages that make up the ProMIS Neurosciences, Inc. website.
PMN310 has been granted Fast Track Designation by the U.S. FDA for the treatment of Alzheimer’s disease.
Browse the links below for pages that make up the ProMIS Neurosciences, Inc. website.